Evidence map›Paper›PMID 33978409›Full record

ArticleACS applied materials & interfaces2021

Innate Immune Invisible Ultrasmall Gold Nanoparticles-Framework for Synthesis and Evaluation.

Geyunjian Harry Zhu, Mohammad Azharuddin, Rakibul Islam, Hassan Rahmoune, Suryyani Deb, Upasona Kanji, Jyotirmoy Das, Johannes Osterrieth, Parminder Aulakh, Hashi Ibrahim-Hashi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. In Vivo Behavior of Ultrasmall Spherical Nucleic Acids.Small (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Geyunjian Harry ZhuDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Mohammad AzharuddinDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
Rakibul IslamDepartment of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
Hassan RahmouneDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Suryyani DebDepartment of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata 700064, India.
Upasona KanjiDepartment of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata 700064, India.
Jyotirmoy DasDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
Johannes OsterriethDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.ORCID http://orcid.org/0000-0002-4724-901X
Parminder AulakhInstitute for Manufacturing (IfM), University of Cambridge, Cambridge CB3 0FS, U.K.
Hashi Ibrahim-HashiDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Raghav ManchandaDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Per H NilssonDepartment of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
Tom Eirik MollnesDepartment of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
Maitreyee BhattacharyyaInstitute of Haematology and Transfusion Medicine, Calcutta Medical College, Calcutta 700073, India.
Mohammad M IslamMassachusetts Eye and Ear and Schepens Eye Research Institute, Dept of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Jorma HinkulaDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
Nigel K H SlaterDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Hirak K PatraDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.ORCID http://orcid.org/0000-0002-6142-5489

Funding

Medical Research Council MR/T030968/1
6 · The paper itself

Abstract

Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed

Indexed as

Biocompatible MaterialsGoldImmunity, InnateMetal NanoparticlesBlood CoagulationCell SurvivalHumansMaterials TestingModels, ImmunologicalSodium CitrateTanninsTHP-1 CellsBiocompatible MaterialsGoldSodium CitrateTanninsbiocompatibilitycoagulation-safecomplement-safeimmunocompatibilityprocess engineeringpro-inflammatory cytokineultrasmall nanoparticles

Identifiers

PMID33978409
PMCPMC8289183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.